Annotation Detail
Information
- Associated Genes
- RRM1
- Associated Variants
-
RRM1 UNDEREXPRESSION
(
ENST00000300738.10 )
RRM1 UNDEREXPRESSION ( ENST00000300738.10 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286).
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2905
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5051
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1257
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Cisplatin,Gemcitabine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 24595080
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cisplatin | Sensitivity | true |
| Gemcitabine | Sensitivity | true |